Source: Annual Congress 2011 - PG3 Workshop: Genomics and proteomics of lung disease



Rating:

Share or cite this content

Citations should be made in the following way:
V. Kinnula (Helsinki, Finland). Proteomics approach in lung disease: the magic tool?. Annual Congress 2011 - PG3 Workshop: Genomics and proteomics of lung disease

Member's Comments

No comment yet.

Related content which might interest you: Genomics and system biology: where does it take us in the future? Source: Annual Congress 2011 - PG3 Workshop: Genomics and proteomics of lung disease Year: 2011 Novel aspects in lung cancer pathology: how does it help for selecting chemotherapy? Source: Annual Congress 2010 - PG4 Core Curriculum Postgraduate Course: Pathology for the clinician Year: 2010 Scene-setting: why do we need genomics and proteomics to understand pathology? Source: Annual Congress 2004 - PG7 - Application of genomics and proteomics to pulmonary disease Year: 2004 Biomarkers in COPD: the search continues! Source: Eur Respir J 2015; 45: 872-874 Year: 2015 Lung function and atherosclerosis: The secret comes to fruition I Source: Annual Congress 2010 - Asthma and COPD: understanding through monitoring Year: 2010 From Bench to edside: Development of a drug to treat lung disease from a basic research start Source: Lung Science Conference 2009 - Cell proliferation, Differentiation and Carcinogenesis Year: 2009 Biomarkers for fibrotic lung disease - new clinical benchmarks from the lab? Source: Annual Congress 2013 –ME3 Biomarkers for fibrotic lung disease – new clinical benchmarks from the lab? Year: 2013 N-ethyl-N-nitrosourea mutagenesis: a new tool for exploring lung disease Source: Annual Congress 2010 - Scientific Year in Review Year: 2010 New technologies in bronchoscopy: which are still research tools and which are ready for clinical use? Source: Annual Congress 2010 - PG13 Core Curriculum Postgraduate Course: Interventional pulmonology Year: 2010 Imaging and molecular biomarkers: a novel approach to screen populations at risk of pulmonary fibrosis? Source: Eur Respir J 2016; 48: 1271-1273 Year: 2016 Early origins of lung disease: towards an interdisciplinary approach Source: Eur Respir Rev, 29 (157) 200191; 10.1183/16000617.0191-2020 Year: 2020 Breath biomarkers for lung cancer detection: ready for use by the pulmonologist? Source: Annual Congress 2012 - PG18 Recent evolutions in screening and early diagnosis of lung cancer Year: 2012 Late Breaking Abstract - Early exploratory use of omic approaches to assess metabolite changes in COPD Source: Virtual Congress 2020 – Chronic lung diseases: novel methods, diagnostics and biomarkers Year: 2020 Interstitial and orphan lung diseases: contribution of the pathologist Source: Annual Congress 2010 - PG4 Core Curriculum Postgraduate Course: Pathology for the clinician Year: 2010 Evaluation of sleepiness: new available tools or still searching for the Holy Grail? Source: Virtual Congress 2021 – Digital health meets sleep breathing disorders Year: 2021 Pharmacogenetics and asthma: false hope or new dawn? Source: Eur Respir J 2007; 29: 1239-1245 Year: 2007 Application of ’omics technologies to biomarker discovery in inflammatory lung diseases Source: Eur Respir J 2013; 42: 802-825 Year: 2013 Disease activity in COPD: time to make imaging biomarkers a PET project? Source: ERJ Open Res, 7 (3) 00445-2021; 10.1183/23120541.00445-2021 Year: 2021